Results 61 to 70 of about 18,827 (200)

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Characterizing Metabolic Alterations in Palbociclib-Resistant ER+ Breast Cancer [PDF]

Characterizing Metabolic Alterations in Palbociclib-Resistant ER+ Breast Cancer Jessica Shunnarah1, Susan M. Dougherty2, Yoannis Imbert-Fernandez3 1ULBB Program, 2Department of Medicine, University of Louisville Abstract Diverse mechanisms of ...
Imbert-Fernandez, Yoannis, Shunnarah, Jessica, Dougherty, Susan M   +2 more
core   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Pharmacokinetics, safety and tolerability of ipatasertib in combination with palbociclib and fulvestrant in patients with advanced breast cancer in a phase Ib study

Frontiers in Pharmacology
IntroductionIpatasertib is a potent, highly selective, small molecule AKT inhibitor that has been evaluated in combination with palbociclib and fulvestrant for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor two ...
Kit Wun Kathy Cheung, Ksenia Arzumanova, Victor Poon, Adam Harris, Ryan Johnson, Frauke Schimmoller, Rucha Sane   +6 more
doaj   +1 more source

Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target

Cell Communication and Signaling, 2019
Background Chondrosarcoma is a malignant cartilaginous neoplasm of the bone which resistant to radiation therapy and chemotherapy. Cyclin-dependent kinase 4 (CKD4) is highly expressed in human cancer, and palbociclib, the inhibitor of CDK4 has been used ...
Zhengxiao Ouyang, Sisi Wang, Ming Zeng, Zhihong Li, Qing Zhang, Wanchun Wang, Tang Liu   +6 more
doaj   +1 more source

CDK4/6 Inhibitors in the Management of Hormone Receptor‐Positive (HR+)/Human Epidermal Growth Factor Receptor 2‐Negative (HER2−) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Evidence‐informed recommendations emphasize the integration of CDK4/6 inhibitors with endocrine therapy as a central component in the management of HR+/HER2− advanced breast cancer in Indonesia. Expanding access and facilitating integration within national treatment frameworks are crucial to improve outcomes and reduce disparities in care.
Sonar Soni Panigoro, Samuel J. Haryono, Prihantono Prihantono, Dedy Hermansyah, Sumadi Lukman Anwar, Yohana Azhar, Febriyanto Kurniawan, Putu Anda Tusta Adiputra, Kristanto Yuli Yarso, Asdi Wihandono   +9 more
wiley   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer

, 2016
The authors reviewed retrospective cases of 2 women — one aged 78 years and the other aged 86 years — with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer treated with combination palbociclib ...
Sowmya Nanjappa, Smitha Pabbathi, Mauricio Valenzuela, David J. Bromberg   +3 more
core   +1 more source

Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials

Cancer Medicine, 2019
Background Palbociclib is a small‐molecule, cyclin‐dependent kinase 4 and 6 inhibitor, which prevents phosphorylation of the retinoblastoma (Rb) protein and inhibits cell‐cycle progression from G1 to S phase.
Linghong Guo, Yuanyuan Hu, Xi Chen, Qingfang Li, Benling Wei, Xuelei Ma   +5 more
doaj   +1 more source

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source